
Y. KOBASHI ET AL. 111
Concerning the diagnostic methods, the bronchoscopic
procedure is important to acquire accurate information
about coincidental pulmonary infection due to Mycobac-
terium species. In this study, four of six patients were
given an accurate diagnosis using bronchoalveolar lavage
fluid (BALF). Although bronchoscopy is an invasive
technique, we think it is necessary to consider a differen-
tial diagnosis of pulmonary NTM disease.
Regarding the selection of treatment, ATS/IDSA pro-
posed a guideline for treatment of pulmonary NTM dis-
ease in 2007 [1]. The therapy for pulmonary MAC dis-
ease was recommended as combined chemotherapy in-
cluding a macrolide (clarithromycin (CAM) or azithro-
mycin (AZM)), ethambutol (EB), rifampicin (RFP) ±
aminoglycoside depending on disease status and/or se-
verity. On the other hand, therapy for pulmonary Myco-
bacterium abscessus or Mycobacterium chelonae disease
was recommended as combined chemotherapy consisting
of a macrolide, aminoglycoside, imipenem and cefoxitin
and that for pulmonary Mycobacterium kansasii disease
was combined chemotherapy including isoniazid (INH),
RFP and EB. There is a little difference in the treatment
between Mycobacterium species. Therefore, it is impor-
tant to identify the species in NTM. However, the clinical
effect of combined chemotherapy for pulmonary NTM
disease except for pulmonary Mycobacterium kansasii
disease was not good (clinical symptoms and/or abnor-
mal radiological findings) [10]. There are no guidelines
for initiating or ending treatment or the adaptation of
treatment for elderly patients. Consequently, combined
chemotherapy was performed for three of six patients
because there were mainly elderly patients in this study;
multi-drug chemotherapy including CAM for two pa-
tients and antituberculous treatment for Mycobacterium
tuberculosis for one. The clinical effect due to combined
chemotherapy was good and the prognosis was also good
despite their general condition. We do not think there
was a relationship between coincidental pulmonary in-
fection and clinical effect or prognosis of the subjects in
this study.
There are a few limitations in this study. Firstly, there
were only a few patients with coincidental pulmonary
infection due to Mycobacterium species among patients
with pulmonary mycobacterial disease in one hospital in
a restricted area, so we need to perform a large-scale
study including several hospitals in Japan to get an accu-
rate of coincidental mycobacterial infection. Secondly,
the rate of coincidental mycobacterial infection was lower
than in other reports [5]. This is because the diagnostic
accuracy of the acid-fast bacilli culture was poor in our
laboratory when patients with coincidental infection due
to Mycobacterium species were tested.
In conclusion, the rate of coincidental pulmonary in-
fection due to Mycobacterium species was a low per-
centage and clinical characteristics were similar to those
of pulmonary MAC disease mainly on the radiological
findings. Although most patients were elderly with un-
derlying diseases, the clinical effect and prognosis were
comparatively good.
REFERENCES
[1] D. E. Griffith, T. Aksamit, B. A. Brown-Elliot, et al., “An
Official ATS/IDSA Statement: Diagnosis, Treatment, and
Prevention of Nontuberculous Mycobacterial Diseases,”
American Journal of Respiratory and Critical Care Medi-
cine, Vol. 175, No. 4, 2007, pp. 367-416.
doi:10.1164/rccm.200604-571ST
[2] The Nontuberculous Mycobacteriosis Control Committee
of the Japanese Society for Tuberculosis, The Scientific
Assembly for Infection and Tuberculosis of the Japanese
Respiratory Society, “Guideline for the Diagnosis of Pul-
monary Nontuberculous Mycobacterial Diseases-2008,”
Kekkaku, Vol. 86, No. 10, 2011, pp. 37-39.
[3] E. Sugihara, N. Hirota, T. Nizeki, et al., “Usefulness of
Bronchial Lavage for the Diagnosis of Pulmonary Disease
Caused by Mycobacterium avium-intracellulare Complex
(MAC) Infection,” Journal of Infection and Chemother-
apy, Vol. 9, No. 4, 2003, pp. 328-332.
doi:10.1007/s10156-003-0267-1
[4] E. Tanaka, R. Amitani, A. Niimi, et al., “Yield of Com-
puted Tomography and Bronchoscopy for the Diagnosis
of Mycobacterium avium Complex Pulmonary Disease,”
American Journal of Respiratory and Critical Care Me-
dicine, Vol. 155, No. 6, 1997, pp. 2041-2046.
doi:10.1164/ajrccm.155.6.9196113
[5] J. Jarand, A. Levin, L. Zhang, et al., “Clinical and Micro-
biologic Outcomes in Patients Receiving Treatment for
Mycobacterium abscessus Pulmonary Disease,” Clinical
Infectious Disease, Vol. 52, No. 5, 2011, pp. 565-571.
doi:10.1093/cid/ciq237
[6] R. J. O’Brien, L. J. Geiter and D. E. Snider, “The Epide-
miology of Nontuberculous Mycobacterial Diseases in the
United States: Results from a National Survey,” Ameri-
can Review Respiratory Disease, Vol. 135, No. 5, 1987,
pp. 1007-1014.
[7] D. E. Griffith, W. M. Girard and R. J. Wallace, Jr., “Cli-
nical Features of Pulmonary Disease Caused by Rapidly
Growing Mycobacteria: An Analysis of 154 Patients,”
American Review Respiratory Disease, Vol. 147, No. 5,
1993, pp. 1271-1278. doi:10.1164/ajrccm/147.5.1271
[8] D. Han, K. S. Lee, W. J. Koh, et al., “Radiographic and
CT Findings of Nontuberculous Mycobacterial Pulmo-
nary Infection Caused by Mycobacterium abscessus,”
American Journal of Roentgenology, Vol. 181, No. 2,
2003, pp. 513-517. doi:10.2214/ajr.181.2.1810513
[9] D. Shitrit, G. L. Baum, R. Pricess, et al., “Pulmonary
Mycobacterium kansasii Infection in Israel, 1999-2004.
Clinical Features, Drug Susceptibility, and Outcome,” Chest,
Vol. 129, No. 3, 2006, pp. 771-776.
doi:10.1378/chest.129.3.771
[10] Y. Kobashi and T. Matsushima, “The Microbiological and
Copyright © 2013 SciRes. OJRD